Literature DB >> 26558523

Outcomes of Repeat Keratoplasty for Failed Therapeutic Keratoplasty.

Shreyas Ramamurthy1, Jagadesh C Reddy2, Pravin K Vaddavalli1, Mohammad Hasnat Ali3, Prashant Garg1.   

Abstract

PURPOSE: To analyze clinical outcomes of repeat optical penetrating (PK) or endothelial keratoplasty (EK) after failed therapeutic keratoplasty (TPK).
DESIGN: Retrospective consecutive, comparative, interventional case series.
METHODS: setting: LV Prasad Eye Institute, Hyderabad, India. STUDY POPULATION: Patients aged >18 years who underwent a repeat PK or EK following a failed TPK with a follow-up of at least 1 year were included. Patients with culture-negative ulcers, viral etiology, coexistent ocular surface disease, and multiple grafts were excluded from the study. INTERVENTION: PK or EK for failed TPK. MAIN OUTCOME MEASURE: Corrected distance visual acuity at 1 year follow-up. secondary outcome measure: Graft clarity.
RESULTS: One hundred twelve eyes (67 PK, 45 EK) were included in the study. The PK group had a significantly higher number of cases with high-risk features prior to regraft. Improvement in visual acuity in each of the types of grafts was statistically significant (P < .01), but there was no difference between the 2 groups at 1 year postoperatively. A statistically significant proportion of grafts regained graft clarity after regrafting in the PK group (P < .01) but not in the EK group (P = .205) at 1 year postoperatively. Endothelial rejection rates were higher in the PK group. Subgroup analysis showed that eyes that had PK or EK for failed TPK conducted for Aspergillus keratitis showed better outcomes in terms of graft clarity. Kaplan-Maier (KM) survival analysis for graft clarity showed cumulative survival of 50% at 5 years. The survival using the KM curve was not statistically different between the 2 groups (P = .33).
CONCLUSION: This study shows that visual rehabilitation with relatively good functional outcomes can be achieved by performing repeat PK or EK in patients after failed TPK.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26558523     DOI: 10.1016/j.ajo.2015.11.004

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Fusarium solani Activates Dectin-1 in Experimentally Induced Keratomycosis.

Authors:  Ling-Juan Xu; Li-Xin Xie
Journal:  Curr Med Sci       Date:  2018-03-15

Review 2.  Surgical management of corneal infections.

Authors:  Sonal Tuli; Matthew Gray
Journal:  Curr Opin Ophthalmol       Date:  2016-07       Impact factor: 3.761

Review 3.  Endothelial keratoplasty versus repeat penetrating keratoplasty after failed penetrating keratoplasty: A systematic review and meta-analysis.

Authors:  Feng Wang; Tao Zhang; Yan Wei Kang; Jing Liang He; Shi-Ming Li; Shao-Wei Li
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

4.  Differential Survival of Penetrating and Lamellar Transplants in Management of Failed Corneal Grafts.

Authors:  Jonathan Aboshiha; Mark N A Jones; Cathy L Hopkinson; Daniel F P Larkin
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

5.  Repeat Keratoplasty for Failed Therapeutic Keratoplasty for Microbial Keratitis: An Analysis of Characteristics and Risk Factors.

Authors:  Jifeng Wan; Jing Lin; Yin Hu; Menghuan Wei; Yingshi Zou; Zhaohui Yuan
Journal:  J Ophthalmol       Date:  2020-02-11       Impact factor: 1.909

6.  Epithelial defects after penetrating keratoplasty in infectious keratitis: An analysis of characteristics and risk factors.

Authors:  Shanshan Wan; Jun Cheng; Yanling Dong; Lixin Xie
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

7.  Outcomes of therapeutic keratoplasty for severe infectious keratitis in Chongqing, a 16-year experience.

Authors:  Qi Zhang; Min Zhao; Mei Xu; Fengjuan Gu; Quan Liu; Yuan Chen; Haiqi Zhang; Aize Kijlstra
Journal:  Infect Drug Resist       Date:  2019-08-12       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.